RxDoctor Payments Data

Joan Brunson, MD

Family Medicine · Alexandria, LANPI 1184616112

Payments from drug & device makers

$11,758in general payments, 2019–2025

Across 748 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$1K
  • AstraZeneca$751
  • Pfizer$721
  • Boehringer Ingelheim$663
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$11,752100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,758 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$211,539
Medicare patients
434
Services billed
2,949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$145,292
MounjaroTirzepatide103$131,662
EliquisApixaban179$99,567
JanuviaSitagliptin Phosphate177$87,750
TrulicityDulaglutide81$86,552
JardianceEmpagliflozin182$86,092
Invega SustennaPaliperidone Palmitate31$83,979
FarxigaDapagliflozin Propanediol113$70,868
IngrezzaValbenazine Tosylate14$50,679
LinzessLinaclotide56$39,983
XareltoRivaroxaban70$28,544
FycompaPerampanel40$23,328
AustedoDeutetrabenazine12$22,502
MyrbetriqMirabegron58$21,214
NuedextaDextromethorphan Hbr/Quinidine22$17,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$463$218,214184 claims
Novo NordiskOzempic$1,089$145,292145 claims
Johnson & JohnsonInvega Sustenna, Xarelto$124$112,523101 claims
Boehringer IngelheimJardiance, Trijardy Xr, Combivent Respimat$663$102,290209 claims
PfizerEliquis$721$99,567179 claims
MerckJanuvia$318$87,750177 claims
AstraZenecaFarxiga$751$70,868113 claims
AbbVieLinzess, Vraylar$2,370$56,41274 claims
Neurocrine Biosciences, Inc.Ingrezza$41$50,67914 claims
Eisai Inc.Fycompa$77$23,32840 claims
Astellas Pharma US IncMyrbetriq$225$21,21458 claims
Avanir Pharmaceuticals, Inc.Nuedexta$13$17,24822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →